| MATERIAL S AND ME THODS

| Study design and treatment
This was a phase I, multicenter, open-label, dose-escalation study of single-agent alpelisib in Japanese patients, with an expansion part at the MTD/RP2D. The expansion part was designed to further evaluate the safety, preliminary efficacy, PK/PD profile, and food effect on the PK profile of alpelisib at the MTD/RP2D.
The dose-escalation part included patients with advanced solid tumors who had progressed despite standard therapy. The expansion part enrolled patients with documented genetic alterations of the PI3K pathway (PIK3CA mutation or amplification). Oral alpelisib was given as a single agent on a continuous 28-day treatment cycle once daily (qd) until unacceptable toxicity, disease progression, investigator's decision, or patient's withdrawal of consent.
The starting dose of alpelisib in Japanese patients was chosen based on the experience in the Western FIH study; the dose was half of the highest dose that had been investigated in Western patients at the time of study start, and at which no dose-limiting toxicities (DLTs) were observed. Five dose levels of alpelisib (90, 180, 270, 350, and 400 mg/day) were investigated in the current study. A maximum of 2 dose reductions or reduction to 60 mg/day alpelisib, whichever was higher, was allowed for each patient in case of toxicity. If a patient required a dose delay of more than 21 days from the intended day of the next scheduled dose, the patient was to be discontinued from the study treatment.
| Patient population
This study enrolled Japanese patients (more than or 18 years) with histologically confirmed, advanced, unresectable solid tumors whose disease had progressed on (or who had not been able to tolerate) standard therapy, or for whom no standard therapy existed. In order to evaluate the sensitivity of PIK3CA-mutant tumors to alpelisib, the expansion part of the study enrolled patients with PIK3CA mutation and/or amplification confirmed by molecular prescreening using an archival or fresh tumor biopsy sample. Patients with measurable or nonmeasurable disease as per RECIST version 1.1, ECOG performance status ≤2, and adequate organ function at screening (including fasting plasma glucose <140 mg/dL/7.8 mmol/L) were eligible. Key exclusion criteria included prior treatment with a PI3K inhibitor, brain metastasis, impaired cardiac function or clinically significant cardiac disease, peripheral neuropathy NCI-CTC grade ≥2, or diarrhea NCI-CTC grade ≥2. Patients were excluded if they had clinically manifested diabetes mellitus (DM), a history of gestational DM, or documented steroid-induced DM.
| Study objectives and endpoints
The primary objective was to estimate the MTD and/or RP2D of oral alpelisib given as a single agent in Japanese patients. The MTD was defined as the highest drug dosage not causing medically unacceptable DLT in more than 33% of the treated patients in the first cycle of treatment. The determination of the MTD was based on the incidence of DLTs during cycle 1. In brief, the DLT was defined an adverse event (AE) or abnormal laboratory value assessed as clinically relevant, occurring 28 days or less following the administration of alpelisib in the first cycle of treatment, which was at least possibly related to alpelisib, unrelated to underlying (tumor) disease, disease progression, intercurrent illness, or concomitant medications, and met any of the criteria defined in the study protocol. Exploratory objectives included assessment of food effect on the full PK profile of alpelisib under fed and fasted conditions after multiple treatments (on cycle 1 day 22 and cycle 2 day 1 in the doseexpansion part) of alpelisib, evaluation of PI3K pathway inhibition in glucose metabolism markers such as fasting glucose and fasting C-peptide in blood, evaluation of PI3K pathway inhibition in skin and tumor tissue using immunochemistry, assessment of relationship between baseline target gene/molecular alteration status and clinical outcome, and assessment of molecular mechanisms of AEs. DCR was defined as the proportion of patients with a best overall response of CR, PR, or stable disease (SD). Progression-free survival was defined as the time from the first date of exposure to study drug to the date of first radiologically documented disease progression or death due to any cause.
| Safety and efficacy assessments
| Pharmacokinetic assessments and biomarkers
Blood samples for PK analyses were obtained on days 1 and 8 of cycle Plasma concentrations of alpelisib were determined using a validated liquid chromatography-mass spectrometry/mass spectrometry method with a lower limit of quantification of approximately 1 ng/mL. The PK parameters were estimated using a noncompartmental method with Phoenix WinNonlin (Princeton, NJ, USA). The dose proportionality of alpelisib was assessed using a power model on log-transformed parameters, ie log (parameter) = log (α) + β*log (dose) + error.
Tumor biopsy samples were collected at screening (pretreatment), on cycle 3 day 1 (4-6 hours postdose), and tumor progression (within 3 days from the last dose) for patients in the escalation as well as expansion parts. Archival formalin-fixed paraffin-embedded tumor samples, representing original diagnostic material and/or a prior tissue-proven recurrence, were collected and assessed for PIK3CA mutation and/or amplification prior to treatment initiation for molecular prescreening. If archival tumor tissue was not available, a fresh tumor biopsy was provided instead. The tumor (archival and/or fresh) material was also analyzed using next-generation sequencing to identify potential biomarkers predictive of efficacy and to assess potential PD biomarkers. Pre-and posttreatment skin biopsies were analyzed at screening, on cycle 3 day 1, and at progressive disease for baseline status and posttreatment changes in p-S6, p-4EBP1, and p-Akt expression. Pre-and posttreatment fresh tumor biopsies were collected at the same time and were paired with blood samples to allow analysis of nonfasting glucose and nonfasting C-peptide levels. In addition, glucose metabolism markers were analyzed on cycle 1 day 2, cycle 1 day 9, and cycle 2 day 2 at pre-dose and 2 and 4 hours postdose.
| Statistical analysis
A Bayesian logistic regression model for dose escalation with overdose control was applied to guide dose escalation and to estimate the MTD in the dose-escalation part. The MTD was defined as the highest drug dosage not causing medically unacceptable DLT in more than 33% of the treated patients in the first cycle of the treatment. 
| Study oversight
This study was approved by the institutional review board or ethics committee at each participating center and was undertaken in accordance with the Good Clinical Practice principles and applicable local regulations. All patients provided written informed consent.
| RE SULTS
| Patients and treatment
Overall, 33 patients (median age, 55 years) were treated with alpelisib tablets on a qd schedule ( Table 1) . Most of the patients (97.0%)
had an ECOG performance status of either 0 or 1 at baseline. The most frequently reported cancer sites were breast and stomach, reported in 4 patients each (12.1%, respectively).
Out of 33 patients, 25 received alpelisib in the dose-escalation part at 5 dose levels (90 mg/day, 3 patients; 180 mg/day, 4 patients; 270 mg/day, 5 patients; 350 mg/day, 6 patients; and 400 mg/day, 7 patients). In the expansion part, 8 patients received alpelisib at the RP2D of 350 mg/day under fasted or fed condition.
All patients discontinued study treatment, with disease progression being the most common reason for discontinuation (63.6%).
Treatment discontinuation due to AEs was reported in 9 patients (27.3%) ( Table 2 ). Maculopapular rash (3 patients, 9.1%) was the most common suspected AE leading to study drug discontinuation.
Maculopapular rash and hyperglycemia were the most common AEs leading to study drug interruption and/or dose adjustment of alpelisib (7 and 6 out of 33 patients, respectively).
In the dose-escalation part, the median duration of exposure to 
| Safety
In the dose-escalation part, 3 DLTs were observed in 2 of the 5 patients who were eligible for the dose-determining set and received 400 mg/day. One patient had grade 3 maculopapular rash and another patient had grade 3 maculopapular rash and grade 2 conjunctivitis. Neither of them met the DLT criteria. However, the investigators judged these events as DLTs based on the total clinical observations. The RP2D of alpelisib as a single agent in Japanese patients was determined as 350 mg/day. The MTD was not determined based on the observed safety and PK data from the CBYL719X1101 study and considering the data from the CBYL719X2101 study, in which antitumor efficacy was observed from 270 mg/day. In the expansion part, 1 out of 8 patients had a DLT (grade 4 infected neoplasm) at 350 mg/ day, whereas no DLT occurred at doses ≤350 mg/day in the doseescalation part (Table 3) . Among 33 patients, the most common AEs (>30%) of any grade, suspected to be related to alpelisib, were hyperglycemia and maculopapular rash (n = 16, 48.5% each), diarrhea (n = 15, 45.5%), and decreased appetite (n = 11, 33.3%) ( 
| Efficacy
Among the 33 patients, 1 patient (3.0%) had PR and 18 patients 
| Expansion part
The safety and PK profile were similar to that of the escalation part.
Six out of 8 patients were eligible for the PAS of the expansion part.
Only 1 patient received 350 mg/day by cycle 2, while for 3 and 2
patients the dose was reduced to 270 mg/day or 180 mg/day before cycle 1 day 22, respectively. A positive food effect was observed on the steady-state PK of alpelisib compared to a fasted state. The geometric mean values of dose-normalized Cmax and AUC0-24 in the fed state were 78% and 56% higher than those in the fasted state, respectively (Table 6 ). These data indicate that food intake had a positive effect on the exposure of alpelisib.
| Biomarker assessments
In the dose-escalation part, an increase in C-peptide levels was observed in most patients, whereas the changes in glucose levels were not consistent. Phosphorylation of AKT, S6, and 4EBP1 in skin biopsy samples tended to decrease after alpelisib treatment. PIK3CA mutation or amplification was detected in tumor tissue (archival samples or fresh biopsy) of 7 out of 33 patients ( Figure 1 , Table 7 ).
Somatic mutations in the TP53 gene were identified in 11 patients.
KRAS, BRAF, and PTEN mutations were identified in tumor samples of 7, 3, and 1 patients, respectively (Table 7) . Three patients had a molecular alteration in BRCA2, and one of these 3 patients, a patient with uterine cancer, was reported to have a PR.
| D ISCUSS I ON
This was a first trial of alpelisib in Japanese patients evaluating the Overall, patients were able to receive >90% of the planned dose at the RP2D. Seventeen patients (51.5%) had relative dose intensity between 90% and 100%. The RP2D and the safety profile determined in Japanese patients are in line with findings from the FIH study evaluating the safety, MTD, and preliminary efficacy of singleagent alpelisib in Western patients with advanced solid tumors with PIK3CA alterations. In the previous study (NCT01219699), the MTDs of alpelisib as a single agent were determined as 400 mg/day and 150 mg twice daily. 11 ln Japanese patients, the most common (more than 30% incidence) all-grade treatment-suspected AEs were hyperglycemia and maculopapular rash (48.5% each), diarrhea (45.5%), and decreased appetite (33.3%). Hyperglycemia is an on-target effect of alpelisib. 11 Hyperglycemia was generally managed by study drug interruption and/or antidiabetic medication. Maculopapular rash was managed by study drug interruption and/or oral antihistamines and topical, oral, and i.v. steroids. The AE profile of alpelisib observed here was also similar to that reported in a randomized phase Ib/II study (NCT01872260), which enrolled patients with ER+, HER2− advanced BC to evaluate the efficacy and safety of alpelisib in combination with letrozole. In this study, the most common (more than TA B L E 6 Summary of statistical analysis of dose-normalized area under the curve from 0 to 24 hours (AUC0-24) and maximal drug concentration (Cmax) by condition (pharmacokinetics analysis set) for the expansion part of a phase I trial of alpelisib in Japanese patients with advanced solid tumors (n = 33) 40% incidence) all-grade AEs included hyperglycemia (62.3%), diarrhea (60.9%), and nausea (44.9%). 13 The safety profile of alpelisib in Japanese patients was also consistent with other isoform-selective PI3K inhibitors, such as the beta-sparing PI3K inhibitor taselisib, in patients with locally advanced or metastatic solid malignancies. Grade 3 or higher AEs that were suspected to be taselisib-related were observed in 41% of patients. Hyperglycemia (15%), rash (12%), fatigue (6%), diarrhea (6%), and pruritus (6%) were the most common grade 3 or higher AEs (>5%) suspected to be related to taselisib. 14 Compared to taselisib (6%), the incidence of alpelisib-related diarrhea of grade 3 or higher was lower in the Western population treated with alpelisib (2.2%)
and not reported (0%) in the Japanese patients in the current trial.
11
In Japanese patients, alpelisib showed encouraging preliminary efficacy. Overall, the ORR was 3% and the DCR was 57.6% (19 of 33 patients). At the RP2D of 350 mg/day, the DCR across all patients 
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